Last Updated : April 24, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Keytruda | pembrolizumab | recurrent, or metastatic cervical cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kerendia | finerenone | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | ||
Ozurdex | dexamethasone intravitreal implant | Diabetic macular edema | Do not reimburse | Complete | ||
Ultomiris | ravulizumab | Atypical hemolytic uremic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Ferriprox | deferiprone | Transfusional iron overload | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
Yescarta | axicabtagene ciloleucel | Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) | Reimburse with clinical criteria and/or conditions | Complete | ||
N/A | abiraterone, prednisone, docetaxel | Metastatic castration sensitive prostate cancer (mCSPC) | Reimburse | Complete | ||
Nubeqa | darolutamide | Metastatic castration-sensitive prostate cancer | Reimburse with clinical criteria and/or conditions | Complete |